Olema Pharma Details Executive Compensation for 2022-2024
Ticker: OLMA · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: OLMA
TL;DR
Olema Pharma's proxy statement shows exec comp details for 2022-2024, focusing on equity awards.
AI Summary
Olema Pharmaceuticals, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on equity awards granted and vested, changes in the fair value of outstanding equity awards, and compensation for both principal executive officers (PEO) and non-PEO named executive officers.
Why It Matters
This filing provides transparency into how Olema Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing disclosing executive compensation, which typically carries low immediate risk.
Key Players & Entities
- Olema Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- 2022-12-31 (date) — Fiscal year end
- 2023-12-31 (date) — Fiscal year end
- 2024-12-31 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
What fiscal years are covered by the compensation data in this filing?
The compensation data covers the fiscal years ending December 31, 2022, 2023, and 2024.
What types of compensation are detailed for the named executive officers?
The filing details equity awards granted, vested, and changes in the fair value of outstanding equity awards.
Who are the categories of executives for whom compensation is reported?
Compensation is reported for Principal Executive Officers (PEO) and Non-PEO Named Executive Officers.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted on April 28, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Olema Pharmaceuticals, Inc. (OLMA).